Drug intelligence / Profile preview

lapatinib + eribulin

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, and eribulin, a microtubule inhibitor. This regimen is primarily used in the treatment of HER2-positive metastatic breast cancer, particularly in patients who have progressed on prior HER2-targeted therapies like trastuzumab. The combination works through complementary mechanisms - lapatinib blocks HER2 and EGFR signaling pathways while eribulin disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on lapatinib + eribulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lapatinib + eribulin.

Explore the full profile